Certara (NASDAQ:CERT) Trading Up 11.5% – Should You Buy?

Certara, Inc. (NASDAQ:CERT)’s share price was up 11.5% on Thursday . The stock traded as high as $5.17 and last traded at $5.2050. Approximately 2,766,645 shares changed hands during mid-day trading, a decline of 18% from the average daily volume of 3,370,438 shares. The stock had previously closed at $4.67.

Analyst Ratings Changes

A number of research analysts recently issued reports on CERT shares. Morgan Stanley lowered their target price on Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Robert W. Baird reduced their price objective on shares of Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Tuesday, May 12th. BMO Capital Markets lowered their price objective on shares of Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Tuesday, May 12th. Barclays dropped their target price on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Finally, KeyCorp cut their target price on shares of Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a research note on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $8.85.

Certara Stock Up 10.7%

The company has a market capitalization of $804.30 million, a price-to-earnings ratio of -51.70 and a beta of 1.53. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.28. The business has a 50-day moving average price of $5.87 and a 200-day moving average price of $7.64.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The company had revenue of $106.92 million during the quarter, compared to analyst estimates of $106.13 million. Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The company’s revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter last year, the business earned $0.14 EPS. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. As a group, equities analysts anticipate that Certara, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Wasatch Advisors LP grew its holdings in shares of Certara by 45.7% during the second quarter. Wasatch Advisors LP now owns 13,532,882 shares of the company’s stock valued at $158,335,000 after buying an additional 4,244,230 shares in the last quarter. Jefferies Financial Group Inc. purchased a new stake in Certara in the 4th quarter worth about $26,706,000. Deerfield Management Company L.P. boosted its position in Certara by 71.7% during the 3rd quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company’s stock worth $82,357,000 after acquiring an additional 2,813,438 shares during the period. Bank of America Corp DE boosted its position in Certara by 292.2% during the 1st quarter. Bank of America Corp DE now owns 2,042,946 shares of the company’s stock worth $11,645,000 after acquiring an additional 1,522,034 shares during the period. Finally, Fort Washington Investment Advisors Inc. OH grew its stake in Certara by 133.4% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 2,272,823 shares of the company’s stock valued at $20,024,000 after acquiring an additional 1,299,109 shares in the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.